October 15 2024 - J&J reports Q3 sales surge of 5.2% despite EPS decline due to M&A activity
Tue, 10/15/24 - 11:38 am
J&J reports Q3 sales surge of 5.2% despite EPS decline due to M&A activity
Medical Marketing and Media
Tue, 10/15/24 - 11:30 am
JNJ
earnings
M&A
Jazz's almost-withdrawn lung cancer drug Zepzelca extends life on top of Roche’s Tecentriq
Fierce Pharma
Tue, 10/15/24 - 11:03 am
Jazz Pharma
Zepzelca
extensive-stage small cell lung cancer
Roche
Tecentriq
AlphaFold’s Nobel Prize is ‘the dawn of a new era’ in mapping drug development potential
Pharma Voice
Tue, 10/15/24 - 10:20 am
AlphaFold
Nobel Prizer
gene mapping
drug development
Human Genome Project
artificial intelligence
Notable Labs files for bankruptcy, ending ambitions for Boehringer cancer drug
Fierce Biotech
Tue, 10/15/24 - 10:17 am
Notable Labs
Boehringer Ingelheim
oncology
bankruptcy
volasertib
Genentech’s Evrysdi helped babies with SMA reach rare milestones in Phase II trial
Clinical Trials Arena
Tue, 10/15/24 - 10:16 am
Roche
SMA
spinal muscular atrophy
Evrysdi
clinical trials
On road to crowded Crohn's disease market, Lilly's Omvoh bests J&J's Stelara in head-to-head study
Fierce Pharma
Tue, 10/15/24 - 10:15 am
Eli Lilly
Crohn's Disease
Omvoh
clinical trials
JNJ
Stelara
Hologic Shells out $350M for Gynesonics
Medical Devices and Diagnostics Industry
Tue, 10/15/24 - 10:14 am
Hologic
Gynesonics
M&A
Medtech
Women's Health
Transgene cervical cancer shot misses the mark in phase 2
Pharmaphorum
Tue, 10/15/24 - 10:12 am
Transgene
vaccines
cervical cancer
clinical trials
J&J, with adult approval in sight, posts adolescent myasthenia gravis data on $6.5B FcRn blocker
Fierce Biotech
Tue, 10/15/24 - 10:10 am
JNJ
nipocalimab
myasthenia gravis
adolescents
Walgreens Loses Another $3 Billion And Plans To Close 1,200 Stores
Forbes
Tue, 10/15/24 - 09:55 am
Walgreens
pharmacies
MilliporeSigma opens new €290m U.S. biosafety testing facility
Biopharma Reporter
Tue, 10/15/24 - 09:19 am
MilliporeSigma
biosafety testing
TPG, Blackstone bid for Bausch + Lomb in potential $14 billion deal
Economic Times
Mon, 10/14/24 - 11:23 pm
Bausch + Lomb
M&A
TPG
Blackstone
Jasper dials up dose after complete responses come and go quickly in hives trial
Fierce Biotech
Mon, 10/14/24 - 11:19 pm
Jasper Therapeutics
chronic hives
FDA, facing pressure, to review position on Zepbound, Mounjaro shortage
BioPharma Dive
Mon, 10/14/24 - 11:17 pm
Eli Lilly
drug shortages
Zebound
Mounjaro
FDA
Astella’s iota receives FDA go-ahead for bladder implant trial
Clinical Trials Arena
Mon, 10/14/24 - 11:16 pm
Astellas
iota Biosciences
FDA
Medtech
underactive bladder
clinical trials
Leqembi's vial design could result in hundreds of millions in annual Medicare waste: study
Fierce Pharma
Mon, 10/14/24 - 11:13 pm
Eisai
Biogen
Leqembi
Alzheimer's disease
October 14 2024 - Cycle Pharma maintains takeover offer for Vanda Pharmaceuticals
Mon, 10/14/24 - 11:42 am
Cycle Pharma maintains takeover offer for Vanda Pharmaceuticals
Reuters
Mon, 10/14/24 - 11:16 am
Vanda Pharmaceuticals
Cycle Pharmaceuticals
M&A
Lilly picks UK for first European Gateway Lab as part of $364M investment plan
Fierce Biotech
Mon, 10/14/24 - 10:28 am
Eli Lilly
Gateway Labs
incubators
Europe

Pages